Raqualia Pharma signs drug development deals with Lazarus Pharmaceuticals

TOKYO, Jun 12 (Pulse News Wire) – RaQualia Pharma Inc. (4579.T) signed two licensing agreements with portfolio companies under Lazarus Pharmaceuticals, LLC for its compounds RQ10 and RQ201,894.

Under the deals, Giathera Pharmaceuticals, Inc. and Giovel Pharmaceuticals, Inc. will lead clinical development and commercialization efforts, while RaQualia will receive milestone payments and royalties based on progress. Additionally, RaQualia secured equity stakes contingent on the success of Giovel's development activities.

This strategic collaboration marks RaQualia’s expansion of its pipeline through external partnerships, aiming to accelerate multiple projects simultaneously. By leveraging Lazarus’ asset-based model, RaQualia seeks to diversify revenue streams and enhance long-term enterprise value. The agreements are expected to contribute to future earnings without immediate impact on the fiscal year ending December 31, 2026. RaQualia plans to continue exploring similar models for additional compounds, focusing on balancing pipeline acceleration and maximizing value creation.

The company will disclose significant developments as they occur.